Skip to main content

Table 2 Dose-volumetric data of target volumes

From: Multi-institutional comparison of treatment planning using stereotactic ablative body radiotherapy for hepatocellular carcinoma – benchmark for a prospective multi-institutional study

   

A

B

C

D

    

Median (Min - Max)

  

Practice-plan

GTV

Dm50

(Gy)

55.2(52.6-55.8)

44.1(43.3-44.2)

49.0(44.2-55.5)

47.9 (46.6 - 48.5)

 

Dm95

(Gy)

53.1(48.8-54.2)

42.7(41.3-43.7)

47.6(44.2-54.3)

47.2 (46.6 - 47.8)

 

Dm98

(Gy)

52.3(47.8-53.8)

42.6(41.1-43.6)

47.5(43.9-54.0)

47.2 (46.4 - 47.7)

 

Min

(Gy)

50.0(49.3-53.1)

42.2(40.9-43.3)

46.8(43.1-53.4)

46.3 (39.6 - 47.0)

 

Max

(Gy)

57.1(57.1-57.1)

45.1(44.6-47.8)

51.8(50.9-57.2)

49.0 (41.2 - 49.7)

PTV

Dm50

(Gy)

51.2(49.5-52.1)

43.6(42.7-44.0)

49.0(46.4-55.4)

47.7 (47.5 - 47.8)

 

Dm95

(Gy)

41.2(41.0-41.5)

41.1(40.7-41.9)

46.5(43.2-53.4)

45.7 (45.5 - 46.5)

 

Dm98

(Gy)

39.0(38.4-39.8)

40.5(39.8-41.3)

45.9(42.5-52.9)

45.3 (44.7 - 46.1)

 

Min

(Gy)

32.5(27.5-34.0)

37.1(35.4-37.3)

40.5(37.7-50.7)

43.7 (41.9 - 45.0)

 

Max

(Gy)

57.1(57.1-57.1)

45.2(44.7-48.9)

40.5(51.7-57.7)

43.7 (48.7 - 49.9)

HI

  

0.34(0.33-0.36)

0.10(0.08-0.19)

0.12(0.08-0.18)

0.08 (0.06 - 0.09)

Vm20 (normal liver)

 

(%)

13.2(6.7-14.1)

12.2(6.5-14.9)

18.9(13.7-22.3)

18.5 (10.1 - 23.2)

MLDm

 

(Gy)

9.3(7.1-11.2)

8.8(7.1-10.4)

12.5(10.9-13.2)

12.2 (8.7 - 14.0)

Protocol-plan1

GTV

Dm50

(Gy)

55.2(52.6-55.8)

42.7(42.0-43.1)

42.0(41.6-43.1)

42.4 (42.2 - 42.7)

 

Dm95

(Gy)

53.1(48.8-54.2)

41.6(40.2-42.0)

40.8(40.6-41.2)

44.5 (41.2 - 42.7)

 

Dm98

(Gy)

52.3(47.8-53.8)

41.5(40.0-42.0)

40.6(40.4-41.0)

41.4 (41.1 - 42.1)

 

Min

(Gy)

50.0(49.0-53.0)

41.0(39.7-42.0)

39.9(39.6-40.4)

41.0 (40.7 - 42.0)

 

Max

(Gy)

57.1(57.1-57.1)

57.1(43.1-46.7)

50.6(43.1-47.6)

45.4 (43.1 - 44.5)

PTV

Dm50

(Gy)

51.2(49.5-52.1)

42.2(41.8-43.1)

42.0(41.6-43.1)

42.0 (41.6 - 42.2)

 

Dm95

(Gy)

41.2(41.0-41.5)

40.0(40.0-40.1)

40.1(40.1-40.2)

40.0 (40.0 - 40.2)

 

Dm98

(Gy)

39.0(38.4-39.8)

39.5(39.4-39.6)

39.7(39.7-39.8)

39.6 (39.2 - 39.8)

 

Min

(Gy)

32.5(27.5-34.0)

36.4(34.1-37.5)

38.9(38.6-39.1)

37.3 (36.6 - 40.7)

 

Max

(Gy)

57.1(57.1-57.1)

44.2(43.3-48.2)

45.1(43.3-48.8)

43.5 (43.4 - 44.5)

HI

  

0.34(0.33-0.36)

0.10(0.09-0.19)

0.11(0.07-0.17)

0.09 (0.07 - 0.10)

CN

  

0.85(0.81-0.91)

0.89(0.80-0.90)

0.63(0.59-0.68)

0.85(0.75 - 0.86)

Vm20 (normal liver)

 

(%)

13.2(6.7-14.1)

11.7(6.2-14.6)

17.5(10.0-19.1)

14.6(8.8 - 15.5)

MLDm

 

(Gy)

9.3(7.1-11.2)

8.8(6.9-9.9)

11.4(8.6-12.3)

10.2 (7.6 - 10.4)

Protocol-plan2

GTV

Dm50

(Gy)

55.2(52.6-55.8)

55.3(53.2-56.3)

53.6(51.6-55.0)

56.2 (55.9 - 56.6)

 

Dm95

(Gy)

53.1(48.8-54.2)

53.2(50.7-55.6)

50.6(48.6-53.3)

52.6 (51.2 - 54.7)

 

Dm98

(Gy)

52.3(47.8-53.8)

52.2(47.4-55.3)

50.1(48.0-52.8)

50.3 (47.4 - 53.0)

 

Min

(Gy)

50.0(49.3-53.1)

51.5(45.0-54.7)

49.7(47.1-53.8)

47.0 (42.6 - 50.5)

 

Max

(Gy)

57.1(57.1-57.1)

57.1(57.1-57.1)

57.1(57.1-57.1)

57.1 (57.1 - 57.1)

PTV

Dm50

(Gy)

51.2(49.5-52.1)

52.5(51.5-54.0)

51.0(49.9-52.3)

53.1 (50.8 - 53.8)

 

Dm95

(Gy)

41.2(41.0-41.5)

40.0(40.0-40.2)

40.1(40.0-40.3)

40.6 (40.4 - 41.3)

 

Dm98

(Gy)

39.0(38.4-39.8)

37.1(36.7-37.7)

37.8(37.4-38.2)

38.5 (36.3 - 38.9)

 

Min

(Gy)

32.5(27.5-34.0)

21.5(18.5-23.6)

26.9(24.9-28.8)

29.5 (25.8 - 32.4)

 

Max

(Gy)

57.1(57.1-57.1)

57.1(57.1-57.1)

57.1(57.1-57.1)

57.1 (57.1 -57.1)

HI

  

0.34(0.33-0.36)

0.37(0.36-0.38)

0.36(0.35-0.39)

0.35 (0.35 -0.39)

CN

  

0.85(0.81-0.91)

0.90(0.88-0.91)

0.89(0.87-0.91)

0.89 (0.85 -0.89)

Vm20 (normal liver)

 

(%)

13.2(6.7-14.1)

11.5(6.3-14.0)

10.4(6.3-13.7)

13.0 (6.8 -13.7)

MLDm

 

(Gy)

9.3(7.1-11.2)

8.3(7.0-9.9)

8.9(8.0-10.9)

9.5 (6.4 - 10.2)

  1. Abbreviations: GTV, gross tumor volume; PTV, planning target volume; HI, homogeneity index; CN, conformation number; MLD, mean liver dose.